Showing results (561-570 of 610) with videos related to
Sort By:
Pageof 61
The New England Journal of Medicine|June 4, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1Mark M Awad, Ryohei Katayama, Michele McTigue, et al.The Lancet. Oncology|November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 studyBenjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2016
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung CancerShirish M Gadgeel, Alice T Shaw, Ramaswamy Govindan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2012
ROS1 rearrangements define a unique molecular class of lung cancersKristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, et al.Elife|February 2, 2017
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancerElsa B Krall, Belinda Wang, Diana M Munoz, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung CancerIbiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, et al.Cell Reports|December 16, 2017
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient CareDavid P Kodack, Anna F Farago, Anahita Dastur, et al.JAMA Oncology|May 22, 2025
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung CancerBiagio Ricciuti, Francesca Fusco, Alissa Cooper, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2014
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014Daniel Morgensztern, Meghan J Campo, Suzanne E Dahlberg, et al.The New England Journal of Medicine|September 30, 2014
Crizotinib in ROS1-rearranged non-small-cell lung cancerAlice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, et al.Pageof 61